Analyst Research
| Report Title | Price |
|---|---|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$414.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Mauna Kea Technologies SAS Announces That First Cellvizio Optical Biopsy Probe Designed for Urological Applications is Now CE Marked
Mauna Kea Technologies SAS announced that its UroFlex confocal miniprobe received CE mark approval for use during cystoscopy procedures. UroFlex is the first optical biopsy probe designed for urological applications and allows the company to enter the EUR 1 billion European urology device market. The new probe allows physicians to obtain optical biopsies that may facilitate the diagnosis, surveillance and treatment of patients with bladder cancer.
Latest Developments for Mauna Kea Technologies SA
Latest Key Developments in Advanced
- Covidien PLC Approves Separation Of Pharmaceuticals Business And Declares Dividend Of Mallinckrodt Ordinary Shares
- Nephros Inc Announces Completion Of Rights Offering
- Volcano Corp Announces Preliminary Results From ADVISE II Study
- Nordion Inc Enters Into Agreement To Divest Targeted Therapies Business To BTG Plc
- Share this
- Link this
- Digg this
Follow Reuters